
Sign up to save your podcasts
Or


In this quick update, I break down the newest Phase 3 data for retatrutide, Lilly’s investigational triple-agonist medication showing unprecedented results in obesity and knee osteoarthritis.
Highlights:
We also cover
A concise medical breakdown to help you stay informed and safe as the obesity-medicine landscape evolves.
By Sasha High5
3434 ratings
In this quick update, I break down the newest Phase 3 data for retatrutide, Lilly’s investigational triple-agonist medication showing unprecedented results in obesity and knee osteoarthritis.
Highlights:
We also cover
A concise medical breakdown to help you stay informed and safe as the obesity-medicine landscape evolves.

1,099 Listeners

210 Listeners

3,170 Listeners

345 Listeners

27,770 Listeners

617 Listeners

419 Listeners

21,194 Listeners

5,097 Listeners

36 Listeners

171 Listeners

144 Listeners

1,759 Listeners

282 Listeners

153 Listeners